京新药业最新一期业绩显示，截至2025一季报，公司营业总收入9.56亿元、同比减少9.86%，归属净利 润1.63亿元，同比减少4.62%，扣非净利润1.47亿元，同比减少6.45%，流动比率1.423、速动比率 0.992、资产负债率28.33%。 通过天眼查大数据分析，浙江京新药业股份有限公司共对外投资了24家企业，参与招投标项目5000次， 知识产权方面有商标信息293条，专利信息225条，此外企业还拥有行政许可149个。 资金流向方面，今日主力资金净流入1.01亿元，占比成交额10.28%。其中，超大单净流入1.10亿元、占 成交额11.17%，大单净流出877.34万元、占成交额0.89%，中单净流出流出6765.60万元、占成交额 6.88%，小单净流出3335.55万元、占成交额3.39%。 来源：金融界 金融界消息 截至2025年8月4日收盘，京新药业（002020）报收于18.11元，上涨10.02%，换手率 7.76%，成交量56.17万手，成交金额9.83亿元。 天眼查商业履历信息显示，浙江京新药业股份有限公司，成立于1999年，位于绍兴市，是一家以从事医 药制造业为主的企业。企业注册资 ...

翰宇药业午后直线拉升涨超10%，海辰药业、阳光诺和、广生堂涨超10%，福源医药、万泽股份涨停， 陇神戎发、京新药业、常山药业、舒泰神等跟涨。 ...

创新药概念股局部走高，京新药业触及涨停，翰宇药业、阳光诺和、广生堂、海辰药业涨超10%。 ...

A股创新药概念股局部反弹，翰宇药业午后直线拉升涨超10%，海辰药业、阳光诺和、广生堂涨超 10%，福源医药、万泽股份涨停，陇神戎发、京新药业、常山药业、舒泰神等跟涨。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 一、回购股份方案的基本情况 浙江京新药业股份有限公司(以下简称"公司")于2025年1月8日召开的第八届董事会第十二次会议，审议 通过了《关于股份回购的方案》，公司使用自有资金以集中竞价交易方式回购公司股份，回购的公司股 份将用于股权激励或员工持股计划。本次回购总金额为不低于人民币20,000万元(含)，不超过人民币 40,000万元（含），回购价格不超过14.80元/股（含），若按回购总金额上、下限和回购股份价格上限 测算，预计回购股份数量约为1,351万股-2,703万股，约占目前公司总股本的1.57%-3.14%。具体回购金 额及回购数量以回购完成时实际使用的资金和回购的股份数量为准。回购股份的实施期限自董事会审议 通过本次回购股份方案之日起12个月内。具体内容详见公司于2025年1月9日、2025年1月10日在《证券 时报》、《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn）上披露的《关于回购股份方案的公 告》（公告编号：202500 ...

Core Viewpoint - Jingxin Pharmaceutical (002020) announced a share buyback plan, intending to repurchase 47.271295 million shares, which represents 5.49% of the company's total share capital as of July 31, 2025 [1] Summary by Category - **Company Announcement** - Jingxin Pharmaceutical plans to repurchase shares through a dedicated securities account via centralized bidding [1] - The total number of shares to be repurchased is 47.271295 million [1] - This repurchase accounts for 5.49% of the company's current total share capital [1]

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、回购股份方案的基本情况 浙江京新药业股份有限公司(以下简称"公司")于 2025 年 1 月 8 日召开的 第八届董事会第十二次会议，审议通过了《关于股份回购的方案》，公司使用自 有资金以集中竞价交易方式回购公司股份，回购的公司股份将用于股权激励或员 工持股计划。本次回购总金额为不低于人民币 20,000 万元(含)，不超过人民币 40,000 万元（含），回购价格不超过 14.80 元/股（含），若按回购总金额上、 下限和回购股份价格上限测算，预计回购股份数量约为 1,351 万股-2,703 万股， 约占目前公司总股本的 1.57%-3.14%。具体回购金额及回购数量以回购完成时实 际使用的资金和回购的股份数量为准。回购股份的实施期限自董事会审议通过本 次回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 1 月 9 日、2025 年 1 月 10 日 在 《 证 券 时 报 》 、 《 中 国 证 券 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露 ...

Group 1 - The company announced a share buyback program, repurchasing 47,271,295 shares, which represents 5.49% of its total share capital [1] - The maximum purchase price for the shares was 14.41 CNY per share, while the minimum purchase price was 11.86 CNY per share [1] - The total amount spent on the share buyback was 608.722 million CNY, excluding transaction fees [1]

Core Viewpoint - The State Council's press conference highlighted the deepening of medical insurance reform during the 14th Five-Year Plan, emphasizing the principle of "anti-involution" in the 11th batch of centralized procurement, which aims to stabilize drug prices and improve profitability in the pharmaceutical industry [1][2]. Group 1: Centralized Procurement and Policy Changes - The National Medical Insurance Administration (NMI) has initiated the 11th batch of centralized procurement, focusing on principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and anti-involution" [1]. - The NMI has optimized procurement rules, moving away from a simple lowest price reference, which previously led to low pricing and affected profitability and quality [2][3]. - The new rules require the lowest bidding companies to justify their pricing and ensure it does not fall below cost, indicating a potential improvement in drug pricing dynamics [1][2]. Group 2: Pharmaceutical Industry Outlook - The pharmaceutical sector is expected to gradually recover from the impacts of centralized procurement, with policy shifts and improved profitability on the horizon [3]. - The industry has seen significant R&D investments, and many companies are entering a phase of product realization, enhancing their competitive edge globally [3]. Group 3: Investment Opportunities - Three main investment lines are suggested: 1. Areas with stable growth, particularly in medical devices and pharmaceuticals, with specific companies highlighted for potential investment [4]. 2. The CXO and medical equipment sectors are anticipated to benefit from favorable domestic financing and fiscal policies, with recommended companies listed [5]. 3. Innovative fields related to national medical insurance negotiations, focusing on companies with international expansion capabilities [5]. - Additional sectors of interest include traditional Chinese medicine, raw materials, medical services, vaccines, and retail pharmacies, with specific companies identified for potential investment [6][7].

Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the benchmark index over the next 6-12 months [10]. Core Insights - The National Healthcare Security Administration (NHSA) has clarified its stance on centralized procurement, emphasizing a "anti-involution" principle, which is expected to stabilize drug prices and improve profitability in the pharmaceutical sector [1][2]. - The NHSA's new procurement rules aim to enhance the quality of drugs and ensure that companies provide reasonable pricing justifications, which is anticipated to lead to a gradual recovery in the profitability of pharmaceutical companies [1][2]. - The pharmaceutical sector is expected to gradually emerge from the impacts of centralized procurement, with a focus on valuation re-evaluation opportunities as policies and corporate earnings improve [1][2]. Summary by Sections Section: Centralized Procurement - The NHSA has initiated the 11th batch of centralized procurement, adhering to principles of stability, quality assurance, and anti-involution, with specific measures to optimize procurement rules [1][2]. - Previous procurement methods primarily focused on price reduction, adversely affecting company profitability and drug quality, but the new measures are expected to foster a healthier competitive environment [1][2]. Section: Investment Opportunities - The report suggests focusing on three main investment lines: 1. Areas with stable growth, particularly in medical devices and pharmaceuticals, where the impact of centralized procurement is gradually dissipating [1][3]. 2. The CXO sector and medical equipment, which are expected to see a reversal due to favorable domestic financing and fiscal policies [1][3]. 3. Innovative fields that are entering a phase of realization or expansion, particularly companies with international capabilities [1][3]. Section: Recommended Stocks - Suggested stocks in the medical device sector include: - Medical consumables: Bairen Medical, Sanyou Medical, Kangwei Century, Dabo Medical, Aikang Medical, Weigao Orthopedics - Ophthalmology: Aibo Medical - Cardiovascular: Huitai Medical, Xinmai Medical, Lepu Medical - In the pharmaceutical sector, recommended stocks include: - Heng Rui Medicine, Xin Li Tai, Jingxin Pharmaceutical, Xianju Pharmaceutical, Kangchen Pharmaceutical [1][3].